Division of Infectious Diseases, Department of Medicine, University of California, San Diego School of Medicine, 9500 Gilman Drive 0760, Biomedical Research Facility Room 4A16, La Jolla, CA, 92093-0760, USA.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe St. E5030, Baltimore, MD, 21205, USA.
Malar J. 2018 Apr 27;17(1):179. doi: 10.1186/s12936-018-2328-z.
A transmission-blocking vaccine (TBV) to prevent malaria-infected humans from infecting mosquitoes has been increasingly considered as a tool for malaria control and elimination. This study tested the hypothesis that a malaria TBV would be acceptable among residents of a malaria-hypoendemic region.
The study was carried out in six Spanish-speaking rural villages in the Department of Loreto in the Peruvian Amazon. These villages comprise a cohort of 430 households associated with the Peru-Brazil International Centre for Excellence in Malaria Research. Individuals from one-third (143) of enrolled households in an ongoing longitudinal, prospective cohort study in 6 communities in Loreto, Peru, were randomly selected to participate by answering a pre-validated questionnaire.
All 143 participants expressed desire for a malaria vaccine in general; only 1 (0.7%) expressed unwillingness to receive a transmission-blocking malaria vaccine. Injection was considered most acceptable for adults (97.2%); for children drops in the mouth were preferred (96.8%). Acceptability waned marginally with the prospect of multiple injections (83.8%) and different projected efficacies at 70 and 50% (90.1 and 71.8%, respectively). Respondents demonstrated clear understanding that the vaccine was for community, rather than personal, protection against malaria infection.
In this setting of the Peruvian Amazon, a transmission-blocking malaria vaccine was found to be almost universally acceptable. This study is the first to report that residents of a malaria-endemic region have been queried regarding a malaria vaccine strategy that policy-makers in the industrialized world often dismiss as altruistic.
预防疟疾病人感染蚊子的传播阻断疫苗（TBV）已越来越多地被视为控制和消除疟疾的一种工具。本研究检验了这样一个假设，即在疟疾低流行地区的居民中，疟疾 TBV 是可以接受的。
该研究在秘鲁亚马逊州洛雷托省的六个西班牙语农村村庄进行。这些村庄由与秘鲁-巴西国际疟疾卓越研究中心相关的 430 户家庭组成。正在洛雷托的 6 个社区进行一项前瞻性纵向队列研究，该研究纳入了 430 户家庭中的三分之一（143 人），通过回答预先验证的问卷，随机选择这些人参与。
所有 143 名参与者都表示普遍希望有一种疟疾疫苗；只有 1 人（0.7%）表示不愿意接种传播阻断疟疾疫苗。对于成年人，注射被认为最容易接受（97.2%）；对于儿童，口服滴剂更受欢迎（96.8%）。随着多次注射的前景（83.8%）和预计的 70%和 50%的不同疗效（分别为 90.1%和 71.8%），接受程度略有下降。受访者清楚地认识到，该疫苗是为社区，而不是个人，提供针对疟疾感染的保护。
在秘鲁亚马逊地区，发现传播阻断疟疾疫苗几乎普遍被接受。这项研究首次报告称，疟疾流行地区的居民已经被问及一种疟疾疫苗策略，而工业化国家的决策者通常认为这种策略是利他主义的。
